Abstract
Toxigenic Clostridium difficile is the most common agent of intestinal Infections In hospitalized patients. The frequency and severity of these infections, including high mortality in the last decade, have increased significantly especially in relation to the incidence of hypervirulent C. difficile strains.
Therapeutic treatment of infection has its drawbacks, particularly in not always reliable effect of standard treatment and a high proportion of recurrences. Fidaxomicin is a new antibiotic with selective effect on C. difficile.
Its advantages, in addition to the high clinical efficacy, include reduced incidence of subsequent recurrence.
